MegaRobo Technologies, a Beijing, China-based provider of automation solutions, raised $300M in Series C funding.
The round was led by Goldman Sachs Asset Management, Asia Investment Capital, and GGV Capital, with participation from Sinovation Ventures, Pavilion Capital, Starr Capital, U-Member Capital, RedView Capital, Harvest Capital and Taihe Capital.
The company intends to use the funds to continue its R&D investment, capacity increasing and global expansion.
Led by CEO Mr. Daniel Huang, MegaRobo has empowered the life sciences industry with a complete suite of automation solutions ranging from benchtop workflow automation for work flow to fully automated platform for complex work flow in large system journey applications, further penetrating into the next-generation life sciences infrastructure system for R&D and AI drug development services. Its workflow automation integrates different processes and applications by combining AI software, analytical instruments, hardware and consumables into one system. Adopted in multiple countries around the world, MegaRobo’s products can improve efficiency for clients compared to conventional approach in various life sciences applications including antibody selection, cell line development and molecular screening.
The company has collaborated with life sciences companies to build the infrastructure and platform to optimize R&D process and improve efficiency. In organoids, the company has partnered with CELLada to achieve high-throughput large-scale cultivation and testing. Various highly valuable organoid models have been cultivated, such as heart organoids with 2-band beating and typical chambers, and brain organoids with ventricles and clear neural structures. In cell & gene therapy, MegaRobo has jointly developed integrated automation solutions for synthetic biology and biopharmaceutical R&D with Agilent Technologies.